ESC ICD Primary Prevention Criteria: Explanation and Clinical Context
The European Society of Cardiology (ESC) 2022 guidance on ventricular arrhythmias and prevention of sudden cardiac death supports the use of implantable cardioverter-defibrillators (ICDs) for primary prevention in patients with symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) when the patient remains at persistently reduced LVEF despite optimal medical therapy (OMT). In practical terms, many guideline summaries and the ESC document use these working thresholds: patients with ischaemic or non-ischaemic cardiomyopathy who have LVEF ≤35% and are in NYHA functional class II–III despite ≥3 months of OMT are typical candidates for consideration of ICD for primary prevention, provided a reasonable expectation of meaningful survival >1 year with good functional status exists. For patients after myocardial infarction, guidelines recommend assessment after the early recovery period (commonly ≥40 days post-MI); in some guideline statements, markedly depressed EF (for example ≤30%) at ≥40 days after MI in selected patients is considered for primary prevention ICD. Additional risk stratifiers (CMR with late gadolinium enhancement, genetic findings, documented non-sustained VT, syncope, EP study results and others) may modify decisions, especially for patients who fall outside simple LVEF/NYHA thresholds; these should be considered in multidisciplinary evaluation.
Reference:
Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Society of Cardiology; 26 Aug 2022.
Kapur N, et al. Primary prevention implantable cardioverter-defibrillator guidance and evidence summaries (review articles and guideline summaries). PubMed/European Heart Journal summaries.
Additional summary discussion on device therapy timing and practical application: device therapy reviews and heart-failure guideline synopses.